Tyra biosciences, inc.TYRA.US Overview
TYRA Overall Performance
TYRA AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
TYRA Key Information
TYRA Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
TYRA Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
TYRA Profile
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Price of TYRA
TYRA FAQ
When is TYRA's latest earnings report released?
The most recent financial report for Tyra biosciences, inc. (TYRA) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TYRA's short-term business performance and financial health. For the latest updates on TYRA's earnings releases, visit this page regularly.
How much debt does TYRA have?
As of the end of the reporting period, Tyra biosciences, inc. (TYRA) had total debt of 6.02M, with a debt ratio of 0.02. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does TYRA have?
At the end of the period, Tyra biosciences, inc. (TYRA) held Total Cash and Cash Equivalents of 99.49M, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is TYRA's EPS continuing to grow?
According to the past four quarterly reports, Tyra biosciences, inc. (TYRA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.47. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of TYRA?
Tyra biosciences, inc. (TYRA)'s Free Cash Flow (FCF) for the period is -23.71M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 121.02% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.